methoxsalen 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
30 298-81-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • 8-MOP
  • methoxsalene
  • 8-Methoxypsoralen
  • 8-Methoxypsoralene
  • deltapsoralen
  • meladinin
  • meladinine
  • meladoxen
  • meloxine
  • methoxsalen
  • oxsoralen
  • xanthotoxin
  • xanthotoxine
A naturally occurring furocoumarin compound found in several species of plants, including Psoralea corylifolia. It is a photoactive substance that forms DNA ADDUCTS in the presence of ultraviolet A irradiation.
  • Molecular weight: 216.19
  • Formula: C12H8O4
  • CLOGP: 2.31
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 0
  • TPSA: 48.67
  • ALOGS: -3.12
  • ROTB: 1
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
10 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Hosey CM, Chan R, Benet LZ
Vd (Volume of distribution) 0.61 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 12 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.09 % Lombardo F, Berellini G, Obach RS
S (Water solubility) 0.02 mg/mL Bocci G, Oprea TI, Benet LZ

Approvals:

DateAgencyCompanyOrphan
Dec. 3, 1954 FDA VALEANT PHARM INTL

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Product use in unapproved indication 284.21 48.19 77 215 179003 63309727

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Product use in unapproved indication 275.31 40.76 82 276 117417 34839156

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Product use in unapproved indication 449.89 39.75 133 470 250226 79493559
Pulmonary embolism 47.75 39.75 24 579 171630 79572155

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC D05AD02 DERMATOLOGICALS
ANTIPSORIATICS
ANTIPSORIATICS FOR TOPICAL USE
Psoralens for topical use
ATC D05BA02 DERMATOLOGICALS
ANTIPSORIATICS
ANTIPSORIATICS FOR SYSTEMIC USE
Psoralens for systemic use
FDA CS M0017973 Psoralens
FDA PE N0000009801 Photosensitizing Activity
FDA MoA N0000010217 Photoabsorption
MeSH PA D003432 Cross-Linking Reagents
MeSH PA D003879 Dermatologic Agents
MeSH PA D007202 Indicators and Reagents
MeSH PA D017319 Photosensitizing Agents
MeSH PA D011838 Radiation-Sensitizing Agents
FDA EPC N0000175879 Psoralen
FDA EPC N0000175984 Photoactivated Radical Generator
CHEBI has role CHEBI:35610 antineoplastic agents
CHEBI has role CHEBI:47868 photosensitising agent
CHEBI has role CHEBI:50177 dermatologic agent
CHEBI has role CHEBI:50684 cross-linking reagents
CHEBI has role CHEBI:76924 plant metabolites

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Vitiligo indication 56727007 DOID:12306
Primary cutaneous T-cell lymphoma indication 400122007
Severe Recalcitrant Psoriasis indication
Lichen planus off-label use 4776004 DOID:9201
Alopecia areata off-label use 68225006 DOID:986
Mycosis fungoides off-label use 118618005
Albinism contraindication 15890002
Aphakia contraindication 24010005
Xeroderma pigmentosum contraindication 44600005 DOID:0050427
Erythropoietic protoporphyria contraindication 51022005 DOID:13270
Systemic lupus erythematosus contraindication 55464009 DOID:9074
Variegate porphyria contraindication 58275005 DOID:4346
Porphyria cutanea tarda contraindication 61860000 DOID:3132
Photosensitivity contraindication 90128006
Bilateral cataracts contraindication 95722004
Hydroa vacciniforme contraindication 200837006
Disease of liver contraindication 235856003 DOID:409
Basal cell carcinoma of skin contraindication 254701007
Pregnancy, function contraindication 289908002
Malignant melanoma contraindication 372244006
Squamous cell carcinoma contraindication 402815007 DOID:1749
Breastfeeding (mother) contraindication 413712001
Porphyria contraindication 418470004




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Acetylcholinesterase Enzyme IC50 6.12 CHEMBL
Cytochrome P450 1A2 Enzyme IC50 7.40 DRUG MATRIX
Amine oxidase [flavin-containing] A Enzyme IC50 4.07 CHEMBL
Taste receptor type 2 member 20 GPCR AGONIST EC50 4.92 IUPHAR
Polyphenol oxidase 2 Enzyme EC50 4.83 CHEMBL

External reference:

IDSource
D00139 KEGG_DRUG
227713 RXNORM
C0025684 UMLSCUI
CHEBI:18358 CHEBI
8MO PDB_CHEM_ID
CHEMBL416 ChEMBL_ID
D008730 MESH_DESCRIPTOR_UI
DB00553 DRUGBANK_ID
12457 IUPHAR_LIGAND_ID
U4VJ29L7BQ UNII
4114 PUBCHEM_CID
400526000 SNOMEDCT_US
41062004 SNOMEDCT_US
4018889 VANDF
11350 MMSL
1906 MMSL
44317 MMSL
5080 MMSL
d01434 MMSL
002018 NDDF

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
UVADEX HUMAN PRESCRIPTION DRUG LABEL 1 64067-216 INJECTION, SOLUTION 20 ug EXTRACORPOREAL NDA 27 sections
Methoxsalen HUMAN PRESCRIPTION DRUG LABEL 1 64380-752 CAPSULE, LIQUID FILLED 10 mg ORAL ANDA 23 sections